Multiple Myeloma: CAR-T First, Bispecifics at Relapse

Two immunotherapy technologies. At least $30 billion in total addressable revenue across all lines of therapy. One will dominate the treatment of relapsed and refractory multiple myeloma. The other will be a complementary tool. The clinical data increasingly answers the sequencing question: CAR-T first, bispecifics at relapse. The stock implications are more nuanced than the clinical answer.

The approved CAR-T products in myeloma produce a 71% reduction in the risk of progression or death versus standard therapy. J&J and Legend’s Carvykti (ciltacabtagene autoleucel) targets BCMA and generated approximately $524 million in quarterly net sales by Q3 2025, with more than 7,500 patients treated. The CARTITUDE-4 Phase 3 trial (NCT04181827) in patients with one to three prior lines showed an 84.6% overall response rate and a 73.1% complete response or better rate, versus 67.3% and 21.8% for standard therapy with daratumumab-pomalidomide-dexamethasone or pomalidomide-bortezomib-dexamethasone. MRD negativity at the 10^-5 threshold was achieved by 60.6% of Carvykti patients versus 15.6% for standard of care. The hazard ratio for progression-free survival was 0.29, a 71% reduction. A 71% reduction in the risk of progression or death is the bar every new myeloma drug has to clear. BMS’s Abecma (idecabtagene vicleucel) was the first BCMA CAR-T approved but has been surpassed commercially and clinically by Carvykti, generating approximately $406 million in total worldwide revenue. Gilead’s (GILD) anito-cel BCMA CAR-T is the next entrant, with a PDUFA date of December 23, 2026. The iMMagine-1 Phase 2 study produced a 96% overall response rate and 74% stringent complete response or complete response rate at a median 15.9 months of follow-up. MRD negativity reached 95% at the 10^-5 threshold. No delayed neurotoxicities have been observed, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome. Gilead acquired Arcellx outright for up to $7.8 billion in February 2026 to maximize its control of the asset.

The bispecific antibody class offers off-the-shelf convenience with solid but shallower efficacy. J&J’s Tecvayli (teclistamab, BCMAxCD3) was the first bispecific approved in myeloma, with a 61.8% overall response rate and 28.2% complete response or better in the registrational MajesTEC-1 trial. Talvey (talquetamab, GPRC5DxCD3) showed 73% ORR in the MonumenTAL-1 trial, with the GPRC5D target offering an alternative antigen when BCMA therapies fail. J&J’s MajesTEC-3 Phase 3 trial read out positive data, with Tecvayli plus Talvey reducing the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed disease. Pfizer’s Elrexfio (elranatamab, BCMAxCD3) received accelerated approval based on MagnetisMM-3 data showing 61% ORR, though its commercial trajectory has been modest. Regeneron’s linvoseltamab (BCMAxCD3) is under FDA review. The bispecific class is expanding rapidly into earlier lines. Both CAR-T and bispecifics represent the expanding role of CAR-T cell therapy, both autologous and allogeneic, in blood cancers.

The sequencing question is where the investment thesis turns. The 2025 International Myeloma Working Group recommendation is CAR-T first, based on two findings. First, prior BCMA-directed bispecific therapy reduces subsequent CAR-T efficacy. In CARTITUDE-2 cohort C, seven patients who received prior BCMA bispecifics before Carvykti showed a 57% ORR and median PFS of only 5 months, versus 97% ORR in CARTITUDE-1 where patients were BCMA-therapy-naive. Real-world data from 236 patients across 16 U.S. academic centers confirmed that prior BCMA-directed therapy, regardless of type, reduced CAR-T response rates and PFS. The effect is duration-dependent: intervals under six months between BCMA bispecific and CAR-T infusion produced the worst outcomes.

Second, the reverse sequence works better. Patients who receive CAR-T first and bispecifics at relapse still achieve meaningful responses. Talquetamab after prior BCMA CAR-T showed a 72% ORR in the MonumenTAL-1 subgroup analysis. BCMA bispecifics after CAR-T also retain efficacy, though with somewhat reduced response rates. The clinical logic is clear: use Carvykti first, which produced a 0.29 hazard ratio in CARTITUDE-4, when T cells are healthiest and the disease burden is lowest.

T-cell fitness is the biological explanation. Bispecific antibodies continuously engage and exhaust T cells. When those exhausted T cells are harvested for CAR-T manufacturing, the resulting product is less potent and less persistent. If a patient uses bispecifics for two or three years before apheresis for CAR-T, the T-cell quality degrades. The IMWG recommends at least four weeks off bispecifics before apheresis and, ideally, a gap of several months. In practice, holding therapy for months in relapsed myeloma is clinically difficult, which means the sequencing decision made at first relapse is effectively the permanent choice.

Cost favors CAR-T in the long run but bispecifics in the short run. CAR-T at $400,000 to $600,000 is a one-time expense. Bispecifics at $10,000 to $15,000 per month cost $120,000 to $180,000 annually. At two years of continuous bispecific therapy, the cost advantage shifts to CAR-T. For Medicare, which covers most myeloma patients, the one-time CAR-T expenditure is simpler than indefinite monthly bispecific billing. The 3 to 6 week vein-to-vein manufacturing time, however, is a genuine clinical problem: patients with aggressive disease progress waiting for CAR-T manufacturing. The companies solving for faster manufacturing or off-the-shelf allogeneic CAR-T address this bottleneck directly, but those approaches have not yet matched autologous CAR-T durability.

Both modalities are moving to frontline treatment, which expands the market by multiples. J&J is running CARTITUDE-5 and CARTITUDE-6 in newly diagnosed myeloma. Tecvayli is in the Monumental-6 frontline trial. The company that gets to frontline first captures the highest-value treatment decision. If CAR-T establishes itself as the curative frontline option and bispecifics are reserved for relapse, CAR-T captures the majority of treatment-naive patients and the highest revenue per patient. First-line CAR-T would be a $10 billion-plus category by itself.

The stock implications split by company positioning. JNJ at $255 and $613B market cap owns both sides of the argument: Carvykti plus Tecvayli plus Talvey. Johnson & Johnson is the only company that wins regardless of which modality dominates. GILD at $135 and $163B market cap is the pure-play CAR-T bet with anito-cel, plus the existing Yescarta and Tecartus franchises in lymphoma. Anito-cel’s December 2026 PDUFA is a binary catalyst: if approved and the safety profile holds (no delayed neurotoxicity is the differentiator), anito-cel could compete directly with Carvykti on efficacy and beat it on safety. BMY at $66 and $130B market cap has Abecma plus the CELMoD mezigdomide with a May 2027 PDUFA, giving it two myeloma assets. But Abecma has lost the efficacy narrative to Carvykti and will face further pressure when anito-cel launches. Pfizer at $25 with modest Elrexfio revenue is a marginal myeloma player. Regeneron at $761 and $80B market cap has linvoseltamab under review but the bispecific market is already crowded with two J&J products. Neither Pfizer nor Regeneron is a myeloma-driven investment thesis.

The verdict: Using CAR-T first, then bispecifics at relapse, is what the real-world data from 236 patients across 16 centers supports. JNJ is the only company that profits from both modalities and is a Hold at $613B because the myeloma franchise is an important growth driver but not large enough to re-rate the stock. GILD is the pure-play CAR-T bet with the nearest catalyst: anito-cel’s December 2026 PDUFA is a stock-moving catalyst, and the safety profile that lacks delayed neurotoxicity is a genuine differentiator versus Carvykti. At $163B, GILD’s HIV franchise dominates the valuation, but anito-cel approval adds a high-margin oncology growth story that could command a higher multiple. The investment case for CAR-T over bispecifics is not which modality has the better data. It is which stocks are priced as if that data matters.